Navigation Links
AIDS Generic Drugs Approved by FDA for Sale in US

Expiry of Patent period for branded Zidovudine in US has lead to approval of FDA for new generic version of AZT, which would cost less and can be imported from other countries.

Zidovudine (AZT), is an anti-retroviral drug used in the // treatment of AIDS, the drug prevents the replication of the virus inside the humans by stopping the multiplication of the virus. The drug is also used in combination with other anti-retroviral drugs to combat HIV infection. Generic drugs of Zidovudine was not available in US market due to strict patent laws, so the people can use only branded Zidovudine drugs, as branded drugs are very costly, treatment using AZT has been very costly in the US. Due to expiry of the patents in the US for Zidovudine, now generic drugs can be sold and brought in US, though generic drugs are cheaper compared to branded drugs, some critics and pharmaceutical giants worry about the quality and safety of using the generic drugs. Now that those patents have expired, versions of drug manufactured by Roxane Laboratories of Columbus, Ohio; Ranbaxy Laboratories of Gurgaon, India, and Aurobindo Pharma of Hyderabad, India, can go on the market. The drug Retrovir which was approved in 1987, manufactured by GlaxoSmithKline and approved by FDA costs about $7 for one 300 milligram tablet.

“These approvals will now allow those infected with HIV more access to these life-saving drugs within our country,” said Mike Leavitt, secretary of the Department of Health and Human Services, in a statement.

(Source: The Associated Press)
'"/>




Page: 1

Related medicine news :

1. Generic drug costs remain shackled
2. FDA Approves Indian Generic Drug For AIDS Treatment
3. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
4. HIV Mortality declining in India due to Generic Antiretroviral therapy drugs
5. Generic Drugs Usage In US Can Save $20 Billion – Express Script Surve
6. Generic Products Compete With GlaxoSmithKline
7. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. First Generic Version of Lexapro permitted by US
10. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
11. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... Illustrate, Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time ... Rights (OCR) HIPAA audit and properly satisfy the law. , Thanks to the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and social campaign, “Humans With Vaginas.” The goal is to ignite conversation via ... non-toxic personal care products. The brand has declared September “Humans with Vaginas” month, ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment ... 8, and Monday, September 11, off work and rolled up their sleeves to help ... to local homes to start the process of rebuilding. , CORDA founder Bonner C. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology: